Biostar Pharmaceuticals Stock Number Of Shares Shorted
| BSPMDelisted Stock | USD 0.01 0.00 0.00% |
Biostar Pharmaceuticals fundamentals help investors to digest information that contributes to Biostar Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Biostar Pink Sheet. The fundamental analysis module provides a way to measure Biostar Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biostar Pharmaceuticals pink sheet.
Biostar |
Biostar Pharmaceuticals Company Number Of Shares Shorted Analysis
Biostar Pharmaceuticals' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Biostar Pharmaceuticals Number Of Shares Shorted | 170.44 K |
Most of Biostar Pharmaceuticals' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostar Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
CompetitionBased on the recorded statements, Biostar Pharmaceuticals has 170.44 K of outstending shares currently sold short by investors. This is 94.67% lower than that of the Pharmaceuticals sector and significantly higher than that of the Pharmaceuticals, Biotechnology & Life Sciences industry. The number of shares shorted for all United States stocks is 96.38% higher than that of the company.
Biostar Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostar Pharmaceuticals' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biostar Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Biostar Pharmaceuticals by comparing valuation metrics of similar companies.Biostar Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Biostar Fundamentals
| Return On Equity | 0.0266 | ||||
| Return On Asset | 0.0425 | ||||
| Profit Margin | 2.94 % | ||||
| Operating Margin | 8.76 % | ||||
| Current Valuation | 316.46 K | ||||
| Shares Outstanding | 2.64 M | ||||
| Number Of Shares Shorted | 170.44 K | ||||
| Price To Book | 0.01 X | ||||
| Price To Sales | 0.0001 X | ||||
| Revenue | 317.79 K | ||||
| Gross Profit | 915.17 K | ||||
| EBITDA | (1.7 M) | ||||
| Net Income | (5.7 M) | ||||
| Cash And Equivalents | 364.97 K | ||||
| Cash Per Share | 0.14 X | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 0.19 X | ||||
| Book Value Per Share | 13.71 X | ||||
| Cash Flow From Operations | 4.91 M | ||||
| Short Ratio | 3.00 X | ||||
| Earnings Per Share | 0.06 X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 200 | ||||
| Beta | -2923.36 | ||||
| Market Capitalization | 94 | ||||
| Total Asset | 42.5 M | ||||
| Retained Earnings | 3.16 M | ||||
| Working Capital | 9.07 M | ||||
| Current Asset | 16.17 M | ||||
| Current Liabilities | 7.1 M | ||||
| Net Asset | 42.5 M |
About Biostar Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostar Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostar Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostar Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Biostar Pink Sheet
If you are still planning to invest in Biostar Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostar Pharmaceuticals' history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |